8 Contract Development and Manufacturing Companies to Watch
AGC Biologics, a Seattle-based leader in protein-based biologics and cell and gene therapies, is significantly advancing its operations.
In June, the company completed a $200 million, 204,514-square-foot manufacturing building at their Copenhagen site, doubling the site’s single-use bioreactor capacity and increasing production by 150 batches of drug product per year. The company also entered into a strategic agreement with Essential Pharma’s rare disease division to produce Hu1418K322A (Hu14.18), a monoclonal antibody for high-risk neuroblastoma.
The Seattle campus remains the focal point of AGC Biologics’ operations, having produced biologics products for over 30 years and serving as the company’s headquarters and center of excellence for global formulation services.